Donanemab-AZBT

Coming off a series of setbacks in amyloidosis and a recent round of layoffs, Prothena is hoping that early data for its Alzheimer's disease (AD) candidate — as well as the potential of a preclinical asset — will attract a partner. The drugmaker shared results on Thursday from the Phase I ASCENT clinical programme, which is evaluating varying dose levels of a once-monthly, subcutaneous anti–beta-amyloid monoclonal antibody (mAb), PRX012, in patients with early symptomatic AD.While Prothena said the candidate was similarly capable of clearing amyloid plaques compared with the two marketed mAbs, Eli Lilly's Kisunla (donanemab-azbt) and Eisai and Biogen's Leqembi (lecanemab), it was linked to higher overall rates of amyloid-related imaging abnormalities with oedema or effusion (ARIA-E).As a result, the company described PRX012 as having a "non-competitive ARIA-E profile" in patients with early symptomatic AD. Still, Chief Development Officer Chad Swanson reiterated Prothena's goal to secure a partnership to advance development of PRX012, as well as its preclinical beta-amyloid transferrin receptor (TfR) antibody PRX012-TfR.The biotech said that observations from ASCENT, as well as feasibility studies of PRX012-TfR, suggest the antibody "may represent an opportunity to significantly lower the risk of ARIA and quickly reduce amyloid plaque with a once-monthly subcutaneous administration," with findings in mice models demonstrating "increased brain exposure and…rapid targeting of beta-amyloid plaques."Plaque attackThursday's readout included data from 228 participants in the ASCENT-2 portion of the programme with early symptomatic AD who were either heterozygous for APOE4, or non-carriers. Individuals who are homozygous for the gene are at higher risk to experience ARIA when receiving an anti–beta-amyloid mAb.Participants were randomised to receive either a 45-mg, 70-mg, 200-mg or 400-mg dose of   PRX012, or placebo. In the 400-mg dose cohort, PRX012 reduced amyloid PET levels to a mean of 27.47 centiloids (CL) at month 12; Kisunla has a defined amyloid negativity threshold of ≤24.1 CL, and Leqembi's is ≤30 CL. However, 41.7% of patients in the high-dose group experienced ARIA-E. Lilly recently presented data from a modified titration schedule of Kisunla showing a 14% incidence rate for the complication (see – Physician Views Results: Kisunla widens its lead over Leqembi with new, safer dosing).Prothena said it does not plan on sharing additional data from ASCENT while it hunts for a partner on its AD assets.

A Phase 1, "first-in-mankind" trial of stem cells injected directly into the brain, is safe with early signs of efficacy; FDA submission made for Phase 2 trial. NEWPORT BEACH, CA, UNITED STATES, August 25, 2025 / EINPresswire.com / -- Regeneration Biomedical, Inc. (RBI), a pioneering biotechnology company developing stem cell therapies for neurodegenerative diseases, today announced results of its FDA-cleared Phase 1 trial evaluating the world’s first direct brain injections of autologous, Wnt-activated stem cells for Alzheimer’s disease. The company has submitted its Phase 1 results to the FDA in support of initiating a Phase 2 multicenter, placebo-controlled trial. The Phase 1 study, conducted at Hoag Memorial Hospital in Newport Beach, CA, involved six participants with mild to moderate Alzheimer’s disease. Each received an infusion of their own ex vivo expanded, Wnt-activated, adipose-derived stem cells in escalated doses. This was achieved by administering the cells through an implanted Ommaya reservoir directly into the brain’s ventricular system—bypassing the blood-brain barrier and allowing the cells to percolate throughout the brain. The trial’s primary endpoint of safety was achieved with a clean profile: no adverse events were observed that were directly attributable to the stem cell injection over 12–72 weeks. Secondary endpoints showed promising early efficacy signals at 12 weeks: p-Tau improved in 80% of evaluable participants, amyloid PET centiloid scores decreased in 60%, ADAS-cog cognitive scoring improved in 80%, and MMSE improved in 60%. “These are results the field has never seen before; certainly with a single agent. After decades of failed Alzheimer’s treatments, our approach not only proved safe but also showed measurable cognitive and biomarker improvements,” said Christopher Duma, M.D., FACS, neurosurgeon, inventor, and Founder & President of Regeneration Biomedical, Inc. “What makes this therapy unique is that we deliver the patient’s own stem cells directly into the brain, bypassing the blood-brain barrier, so they can reach every nook and cranny where Alzheimer’s does its damage. This represents a disruptive paradigm shift in the treatment of Alzheimer’s disease.” Why it’s different • Direct-to-brain vs. IV antibodies: Recently approved monoclonal antibodies (Biogen/Eisai’s Leqembi/lecanemab and Eli Lilly’s Kisunla/donanemab) are administered IV and carry known risks of amyloid-related imaging abnormalities (ARIA) and infusion-related reactions; they require baseline and frequent MRI monitoring per FDA labels. RBI’s autologous stem cells are delivered intraventricularly to bypass the blood-brain barrier and distribute broadly via cerebrospinal fluid. (FDA Access DataU.S. Food and Drug Administration.) • Factual safety context for antibodies (per FDA labels): In Leqembi’s pivotal study, ARIA-E occurred in 13% and ARIA-H in 14%, and infusion-related reactions in 26%, vs 2%, 8%, and 7% on placebo. Kisunla reported any ARIA in 36% (ARIA-E 24%, ARIA-H 31%) and infusion reactions 9% in Study 1; with a gradual dosing regimen (Study 2), ARIA-E ~16% and infusion reactions 16% were observed. MRI monitoring is specified before the 2nd, 3rd, 4th, and 7th infusions for Kisunla. (FDA Access Data U.S. Food and Drug Administration FDA Access Data.) There have been no such adverse events with the RBI cells. • Leqembi and Kisunla do not improve cognition, they only slow the cognitive deterioration. RBI’s autologous cells appear to improve cognition in this very early study. • Independent media context: At CTAD 2024, BioSpace covered RBI’s direct-to-brain approach and early signals (reduced p-Tau and amyloid, MMSE trending up in the initial cohort) alongside discussions of ARIA risk with antibody therapies. https://www.biospace.com/drug-development/leqembi-kisunla-and-beyond-the-next-wave-of-alzheimers-at-ctad-2024 Important note: Mechanisms differ (cell therapy vs. antibodies), and cross-trial comparisons have limitations. RBI’s Phase 1 was designed primarily for safety with a small, open-label cohort; findings are preliminary and will be tested in a larger, controlled study. Looking Ahead: Phase 2 Trial RBI has submitted its Phase 1 findings to the FDA and is preparing to launch a multi-site, placebo-controlled Phase 2 trial in the United States, and is pioneering autologous stem cell therapies for Alzheimer’s disease and other neurodegenerative conditions. Additional trials for Parkinson’s disease, ALS, multiple sclerosis, and chronic traumatic encephalopathy (CTE) are also planned. About Regeneration Biomedical, Inc. Founded in 2018 by neurosurgeon Christopher Duma, M.D., FACS, Regeneration Biomedical, Inc. is building on preclinical and early clinical experience. RBI is advancing first-in-human disruptive approaches aimed not only at slowing disease progression but at restoring brain function. Media Contact Christopher Duma, MD, FACS Regeneration Biomedical, Inc. Email: chris@regenerationbiomedical.com Phone: 949-689-9529 www.regenerationbiomedical.com Christopher Duma Regeneration Biomedical, Inc. +1 949-689-9529 CHRIS@REGENERATIONBIOMEDICAL.COM Visit us on social media: LinkedIn Instagram Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.